Cryoport Inc Revenue Growth Rates (CYRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cryoport inc   (NASDAQ: CYRX)
 

CYRX's Revenue Growth by Quarter and Year

Cryoport Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 48.97
1st Quarter March 47.80
FY 96.77

CYRXs Annual Revenue
Cryoport Inc 's Revenue in the fiscal year 2025 $ 176.18 millions
Cryoport Inc 's Revenue in the fiscal year 2024 $ 228.39 millions
Cryoport Inc 's Revenue in the fiscal year 2023 $ 233.26 millions
Cryoport Inc 's Revenue in the fiscal year 2022 $ 237.28 millions
Cryoport Inc 's Revenue in the fiscal year 2020 $ 222.61 millions




CYRX Revenue second quarter 2026 Y/Y Growth Comment
Cryoport inc reported Revenue growth of 7.75% year on year in the second quarter 2026, to $ 48.97 millions, this is lower than Cryoport Inc 's recent average Revenue rise of 82.13%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue growth. While Cryoport Inc ' s Revenue increase of 7.75% ranks overall at the positon no. 2992 in the second quarter 2026.


CYRX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -23.65 % 3.96 % -5.14 %
3rd Quarter September - 15.42 % -31.77 % -7.11 %
2nd Quarter June 7.75 % 14.45 % -30.36 % -11.11 %
1st Quarter March 16.47 % 10.06 % -40.64 % 20.11 %
FY   - 0.75 % -25.04 % -

Financial Statements
Cryoport Inc 's second quarter 2026 Revenue $ 48.97 millions CYRX's Income Statement
Cryoport Inc 's second quarter 2025 Revenue $ 45.45 millions Quarterly CYRX's Income Statement


CYRX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2.76 % 55.35 % 1.96 %
3rd Quarter September - -2.68 % -3.5 % -1.51 %
2nd Quarter June 2.45 % 10.75 % 6.49 % -9.23 %
1st Quarter March 5.17 % -31.06 % -34.88 % 4.08 %
FY (Year on Year)   - 0.75 % -25.04 % -


Back to CYRX Growth rate Comparisons >> Back to CYRX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #415
Overall #2992

Revenue Y/Y Growth Statistics
High Average Low
660.59 % 82.13 % -69.58 %
(Mar 31 2013)   (Mar 31 2012)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #415
Overall #2992
Revenue Y/Y Growth Statistics
High Average Low
660.59 % 82.13 % -69.58 %
(Mar 31 2013)   (Mar 31 2012)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cryoport Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
144154 % 4009.04 % -100 %
(Dec 31 2011)  


CYRX's II. Quarter Q/Q Revenue Comment
Cryoport inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.45% quarter on quarter, to $ 48.97 millions.

Within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Revenue quarter on quarter growth. While Cryoport Inc 's Revenue growth quarter on quarter, overall rank is 1414.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #195
Overall #1414
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #195
Overall #1414
Revenue Q/Q Growth Statistics
High Average Low
144154 % 4009.04 % -100 %
(Dec 31 2011)  


CYRX's II. Quarter Q/Q Revenue Comment
Cryoport inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.45% quarter on quarter, to $ 48.97 millions.

Within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Revenue quarter on quarter growth. While Cryoport Inc 's Revenue growth quarter on quarter, overall rank is 1414.


Cryoport Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 186.45 $ 182.94 $ 176.18 $ 190.26 $ 184.34
Y / Y Revenue Growth (TTM) 1.14 % 2.43 % 0.76 % 10.25 % -3.19 %
Year on Year Revenue Growth Overall Ranking # 3166 # 2133 # 1988 # 1230 # 2276
Seqeuential Revenue Change (TTM) 1.92 % 3.84 % -7.4 % 3.21 % 3.22 %
Seq. Revenue Growth (TTM) Overall Ranking # 2992 # 2173 # 1754 # 1027 # 1857


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Cryoport Inc 's cumulative twelve months Revenue were $ 186 millions, company would post below average annual Revenue growth of 3.22% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Cryoport Inc 's Revenue growth from the 47.8% growth in Mar 31 2026.

In the Healthcare sector 423 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2133 to 3166.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 424
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
660.59 %
 82.13 %
-69.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 415
S&P 500 # 2992
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Cryoport Inc 's cumulative twelve months Revenue were $ 186 millions, company would post below average annual Revenue growth of -69.58% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Cryoport Inc 's Revenue growth from the 47.8% growth in Mar 31 2026.

In the Healthcare sector 423 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2133 to 3166.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 424
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
660.59 %
82.13 %
-69.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 415
S&P 500 # 2992




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions


About Cryoport Inc Revenue Growth Rates (CYRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cryoport Inc (CIK 1124524).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-092107
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cryoport Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.